Merck, Daiichi Sankyo Pull FDA Application for Lung Cancer Drug - Merck & Co (NYSE:MRK)
Merck (NYSE: MRK) and Daiichi Sankyo withdrew their FDA application for lung cancer drug ifinatamab deruxtecan due to insufficient data for accelerated approval. The drug showed a 48.2% response rate in trials. Phase 3 trials continue. Merck also licensed a KRAS G12D inhibitor from SciBrunch for $2.13B, including a $400M upfront payment.
How this was made
The 30-second read
Why it matters
The withdrawal signals regulatory concerns and removes a near‑term growth catalyst, likely prompting short‑term sell pressure.
Market read
Regulatory setback for a major oncology asset could affect pharma sector sentiment and related biotech stocks.
What to watch
The phase‑3 trials continue, preserving some upside potential if later data are positive.
Background
Merck and Daiichi Sankyo had been pursuing accelerated approval for I‑DXd, an antibody‑drug conjugate for extensive‑stage small‑cell lung cancer.
Ticker impact
Merck and Daiichi Sankyo withdrew their FDA BLA for the lung cancer drug I-DXd, a new regulatory setback.
likely pressure as the market prices in the lost revenue opportunity
Regulatory withdrawal is a material negative catalyst for a large pharma; investors typically react with sell pressure.
Market effects
May dampen sentiment for the broader oncology biotech sector.
US pharma stocks could see modest downside.
Limited to companies with similar lung‑cancer pipelines.
Counterpoint
If the companies can pivot to other indications, the long‑term impact may be muted.
Key entities
- companyMerck & Co., Inc.
US‑listed pharmaceutical giant (ticker MRK).
- companyDaiichi Sankyo Co., Ltd.
Japanese pharma with US ADR ticker DSKY.
